Have a feature idea you'd love to see implemented?
Let us know!
NRXP NRX Pharmaceuticals Inc
Price (delayed)
$1.21
Market cap
$13.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.69
Enterprise value
$19.88M
Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination
Highlights
NRXP's EPS has surged by 53% year-on-year and by 15% since the previous quarter
NRX Pharmaceuticals's net income has increased by 36% YoY and by 3.2% from the previous quarter
NRX Pharmaceuticals's quick ratio has plunged by 88% YoY but it has increased by 14% from the previous quarter
NRX Pharmaceuticals's debt has decreased by 32% YoY but it has increased by 27% from the previous quarter
The company's equity fell by 22% QoQ
Key stats
What are the main financial stats of NRXP
Market
Valuations
Earnings
Shares outstanding
10.89M
Market cap
$13.18M
Enterprise value
$19.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$24.47M
EBITDA
-$24.46M
Free cash flow
-$13.99M
Per share
Balance sheet
Liquidity
EPS
-$2.69
Free cash flow per share
-$1.33
Book value per share
-$1.72
Revenue per share
$0
TBVPS
$0.5
Total assets
$5.26M
Total liabilities
$23.66M
Debt
$8.59M
Equity
-$18.39M
Working capital
-$18.78M
Debt to equity
-0.47
Current ratio
0.21
Quick ratio
0.08
Net debt/EBITDA
-0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-336.9%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRXP stock price
How has the NRX Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-4.35%
1 month
-24.84%
1 year
-56.47%
YTD
-73.7%
QTD
-28.4%
Financial performance
How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.26M
Net income
-$24.82M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 37% YoY and by 4.7% from the previous quarter
NRX Pharmaceuticals's net income has increased by 36% YoY and by 3.2% from the previous quarter
Growth
What is NRX Pharmaceuticals's growth rate over time
Valuation
What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NRXP's EPS has surged by 53% year-on-year and by 15% since the previous quarter
The company's equity fell by 22% QoQ
Efficiency
How efficient is NRX Pharmaceuticals business performance
NRX Pharmaceuticals's ROA has plunged by 99% YoY and by 45% from the previous quarter
Dividends
What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRXP.
Financial health
How did NRX Pharmaceuticals financials performed over time
The total assets is 78% less than the total liabilities
NRX Pharmaceuticals's quick ratio has plunged by 88% YoY but it has increased by 14% from the previous quarter
NRX Pharmaceuticals's current ratio has plunged by 76% YoY but it has increased by 17% from the previous quarter
NRX Pharmaceuticals's debt is 147% more than its equity
The debt to equity has soared by 90% YoY but it has contracted by 4.4% from the previous quarter
NRX Pharmaceuticals's debt has decreased by 32% YoY but it has increased by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.